

Felimazole 5 mg/ml oral solution for cats

Authorised

- Thiamazole

Product identification

Medicine name:

Felimazole 5 mg/ml oral solution for cats

Active substance:

Thiamazole

Target species:

Cat

Route of administration:

Oral use

Product details

Active substance and strength:

Thiamazole

5.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Oral solution

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QH03BB02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Poland

Available in:

Poland

Package description:

Polyethylene terephthalate (PET) amber bottle of 30 ml, closed with a low density polyethylene (LDPE) plug and a high density polyethylene (HDPE) closure. The veterinary medicinal product is supplied with a 1 ml polyethylene (PE) / polypropylene (PP) measuring syringe for administration of the solution to the animal. The syringe is graduated in 0.25 mg increments up to 5 mg. Each closed bottle and accompanying syringe is contained in a cardboard carton.

Polyethylene terephthalate (PET) amber bottle of 100 ml, closed with a low density polyethylene (LDPE) plug and a high density polyethylene (HDPE) closure. The veterinary medicinal product is supplied with a 1 ml polyethylene (PE) / polypropylene (PP) measuring syringe for administration of the solution to the animal. The syringe is graduated in 0.25 mg increments up to 5 mg. Each closed bottle and accompanying syringe is contained in a cardboard carton.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - known active substance (Article 8 of Regulation (EU) 2019/6)

Marketing authorisation holder:

Dechra Regulatory B.V.

Marketing authorisation date:

27/03/2024

Manufacturing sites for batch release:

Genera d.d.

Responsible authority:

Office For Registration Of Medicinal Products Medical Devices And Biocidal Products

Authorisation number:

3306

Date of authorisation status change:

27/03/2024

Reference member state:

Ireland

Procedure number:

IE/V/0505/004

Concerned member states:

Austria Belgium Bulgaria Croatia Czechia Denmark Finland France
Germany Greece Hungary Italy Luxembourg Netherlands Norway Poland
Portugal Romania Slovakia Slovenia Spain Sweden
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.